1. Published

   Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

   Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Nov 2003.

   Research output: Contribution to conference › Paper

2. Published

   Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

   Hughes, D., Hughes, D. A. & Pirmohamed, M., 1 Nov 2003, In: Value in Health. 6, 6, p. 749

   Research output: Contribution to journal › Article › peer-review

3. Published

   Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

   Hughes, D. & Hughes, D. A., 1 Jun 2003.

   Research output: Contribution to conference › Paper

4. Published

   Abolition of prescription charges in Wales: the impact on medicines use in those who used to pay

   Hughes, D., Groves, S., Cohen, D., Alam, M. F., Dunstan, F. D., Routledge, P. A., Hughes, D. A. & Myles, S., 1 Dec 2010, In: International Journal of Pharmacy Practice. 18, 6, p. 332-340

   Research output: Contribution to journal › Article › peer-review

5. Published

   Abolition of prescription copayments in Wales: an observational study on dispensing rates.

   Hughes, D., Cohen, D., Alam, M. F., Dunstan, F. D., Myles, S., Hughes, D. A. & Routledge, P. A., 1 Aug 2010, In: Value in Health. 13, 5, p. 675-680

   Research output: Contribution to journal › Article › peer-review

6. Published

   Access to timely care in Portugal as compared to other European countries

   Woods, R. T., Pereira, M. G., Stephan, A., Verhey, F., de Vugt, M., Wolfs, C., Handels, R., Verbeek, H., Kerpershoek, L., Bieber, A., Meyer, G., Marques, M., Barrios, H., Balsinha, C., Woods, R., Wimo, A., Selbaeck, G., Irving, K. & Zannetti, O., 1 Dec 2015, In: International Psychogeriatrics. 27, 1, p. S35-S36

   Research output: Contribution to journal › Article › peer-review

7. Published

   Accounting for non-compliance in pharmacoeconomic evaluations.

   Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Jan 2001, In: Pharmacoeconomics. 19, 12, p. 1185-1197

   Research output: Contribution to journal › Article › peer-review

8. Published

   Accurate and practical dosing of African populations using a height, weight and age model designed for lapdap

   Hughes, D., Hughes, D. A. & Bagust, A., 1 Nov 2002.

   Research output: Contribution to conference › Paper

9. Published

   Activity Increase Despite Arthritis (AÏDA): design of a Phase II randomised controlled trial evaluating an active management booklet for hip and knee osteoarthritis [ISRCTN24554946]

   Williams, N., Amoakwa, E., Burton, K., Hendry, M., Belcher, J., Lewis, R., Hood, K., Jones, J. G., Bennett, P., Edwards, R. T., Neal, R., Andrew, G. & Wilkinson, C., 4 Sept 2009, In: BMC Family Practice. 10, 62, p. 1-9 62.

   Research output: Contribution to journal › Article › peer-review

10. Published

    Activity Increase Despite Arthritis (AÏDA): phase II randomised controlled trial of an active management booklet for hip and knee osteoarthritis in primary care

    Williams, N. H., Amoakwa, E., Belcher, J., Edwards, R. T., Hassani, H., Hendry, M., Burton, K., Lewis, R., Hood, K., Jones, J., Bennett, P., Linck, P. G., Neal, R. D. & Wilkinson, C. E., 1 Aug 2011, In: British Journal of General Practice. 61, 589, p. e452-e458

    Research output: Contribution to journal › Article › peer-review

11. Published

    Additional therapy for young children with spastic cerebral palsy: a randomised controlled trial.

    Weindling, A. M., Cunningham, C. C., Glenn, S. M., Edwards, R. T. & Reeves, D. J., 1 May 2007, In: Health Technology Assessment. 11, 16, p. 90

    Research output: Contribution to journal › Article › peer-review

12. Published

    Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis

    Bellis, M. A., Williams, R., Aspinall, R., Bellis, M., Camps-Walsh, G., Cramp, M., Dhawan, A., Ferguson, J., Forton, D., Foster, G., Gilmore, I., Hickman, M., Hudson, M., Kelly, D., Langford, A., Lombard, M., Longworth, L., Martin, N., Moriarty, K., Newsome, P., O'Grady, J. & Pryke, R., 27 Nov 2014, In: The Lancet. 384, 9958, p. 1953-1997

    Research output: Contribution to journal › Article › peer-review

13. Published

    Adherence and variability in warfarin dose requirements: assessment in a prospective cohort

    Hughes, D., Jorgensen, A. L., Hughes, D. A., Hanson, A., van Eker, D., Toh, C. H., Pirmohamed, M. & Williamson, P. R., 1 Jan 2013, In: Pharmacogenomics. 14, 2, p. 151-163

    Research output: Contribution to journal › Article › peer-review

14. Published

    Adherence of patients to long-term medication: a cross-sectional study of antihypertensive regimens in Austria

    Lotsch, F., Auer-Hackenberg, L., Groger, M., Rehman, K., Morrison, V. L., Holmes, E. A., Parveen, S., Plumpton, C. O., Clyne, W., de Geest, S., Dobbels, F., Vrijens, B., Kardas, P., Hughes, D. & Ramharter, M., May 2015, In: Wiener klinische Wochenschrift. 127, 9-10, p. 379-384

    Research output: Contribution to journal › Article › peer-review

15. Published

    Adherence with HAART: pharmacoeconomic considerations

    Hughes, D. & Hughes, D. A., 1 Jun 2007.

    Research output: Contribution to conference › Paper

16. Published

    Adverse childhood experiences and associations with health-harming behaviours in young adults: surveys in eight eastern European countries

    Bellis, M. A., Hughes, K., Leckenby, N., Jones, L., Baban, A., Karcheva, M., Povilaitis, R., Pudule, I., Qirjako, G., Ulukol, B. & Raleva, M. T., 19 Jun 2014, In: Bulletin of the World Health Organization. 92, p. 641-655B

    Research output: Contribution to journal › Article › peer-review

17. Published

    Adverse childhood experiences: retrospective study to determine their impact on adult health behaviours and health outcomes in a UK population.

    Bellis, M. A., Lowey, H., Leckenby, N., Hughes, K. & Harrison, D., 14 Apr 2013, In: Journal of Public Health. 36, 1, p. 81-91

    Research output: Contribution to journal › Article › peer-review

18. Published

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Jul 2007.

    Research output: Contribution to conference › Paper

19. Published

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Mar 2007.

    Research output: Contribution to conference › Paper

20. Published

    Adverse drug reactions in economic evaluations

    Hughes, D. & Hughes, D. A., 1 Jan 2007, In: Value in Health. 10, 3, p. A109

    Research output: Contribution to journal › Article › peer-review

21. Published

    Adverse drug reactions: analysis by regulatory authorities and by economists

    Hughes, D. & Hughes, D. A., 1 Apr 2007.

    Research output: Contribution to conference › Paper

22. Published

    Alcohol age of initiation and long-term impact: a cross sectional survey of adults in England

    Morleo, M., Jones, L. & Bellis, M. A., 30 Oct 2014, In: Journal of Substance Use.

    Research output: Contribution to journal › Article › peer-review

23. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

24. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Alemtuzumab (MabCampath) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

25. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Ambrisentan (Volibris) for pulmonary arterial hypertension.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2009, 2009 ed. Unknown.

    Research output: Book/Report › Commissioned report

26. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Anidulafungin (Ecalta) for the treatment of invasive candidiasis in adult non-neutropenic patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2009, 2009 ed. Unknown.

    Research output: Book/Report › Commissioned report

27. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-experienced patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

28. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Atazanavir (Reyataz) in treatment-naïve patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

29. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Buprenorphine/naloxone (Suboxone) as substitution treatment for opioid dependence.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

30. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Deferasirox (Exjade) for the treatment of chronic iron overload due to blood transfusions.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

31. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Docetaxel (Taxotere) for locally advanced squamous cell carcinoma of the head and neck.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

32. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Emtricitabine/tenofovir DF (Truvada)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

33. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Epoetin delta (Dynepo)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

34. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for STEMI.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

35. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Fondaparinux Sodium (Arixtra®) for UA/NSTEMI.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

36. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Icatibant (Firazyr) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

37. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Lenalidomide (Revlimid) for multiple myeloma.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

38. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Maraviroc (Celsentri) for treatment-experienced adults infected only with CCR5-tropic HIV-1.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2009, 2009 ed. Unknown.

    Research output: Book/Report › Commissioned report

39. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Pegfilgrastim (Neulasta) for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

40. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Raltegravir (Isentress) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

41. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Rufinamide (Inovelon) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

42. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Stiripentol (Diacomit) for use in conjunction with clobazam and valproate in patients with severe myoclonic epilepsy in infancy.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

43. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Tacrolimus (Advagraf) for the prophylaxis of transplant rejection in adult kidney or liver allograft recipients and the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2009, 2009 ed. Unknown.

    Research output: Book/Report › Commissioned report

44. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Tenofovir disoproxil fumarate (Viread) for the treatment of hepatitis B.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

45. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Teriparatide (Forsteo) for the treatment of osteoporosis in men at increased risk of fracture.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

46. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Topotecan (Hycamtin®) for Small Cell Lung Carcinoma.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

47. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Trabectedin (Yondelis) for advanced soft tissue sarcoma.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

48. Published

    All Wales Medicines Strategy Group Final Appraisal Report - Ziconotide (Prialt) for the intrathecal treatment of severe, chronic pain.

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2008, 2008 ed. Unknown.

    Research output: Book/Report › Commissioned report

49. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Clofarabine (Evoltra)

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report

50. Published

    All Wales Medicines Strategy Group Final Appraisal Report – Co-careldopa intestinal gel (Duodopa).

    Hughes, D., Hughes, D. A. & All Wales Strategy Group., [. V., 1 Jan 2007, 2007 ed. Unknown.

    Research output: Book/Report › Commissioned report